Lava Therapeutics Nv Expected To Post A Loss Of 62 Cents A Share: Earnings Preview

LAVA Therapeutics NV

20/03/2023 12:44

* LAVA Therapeutics NV  LVTX.OQ   LVTX.O  is expected
to show a
rise in quarterly revenue when it reports  results on March 22
(estimated). 
    * The Utrecht-based  company is expected to report  a
19.9% increase in revenue to $1.2 million from $1 million a year
ago, according to the mean estimate from 5 analysts, based on
Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for LAVA Therapeutics
NV is
for a loss of 62 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for LAVA
Therapeutics
NV is $15.5​, above​ its last closing price of $1.66. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  0.00        -0.14      0.04      Beat    128.9
 Jun. 30 2022  -0.63       -0.63      -0.31     Beat    50.5
 Mar. 31 2022  -0.84       -0.86      -0.41     Beat    54.8​
 Dec. 31 2021  -0.41       -0.41      -0.38     Beat    7.8
 ​​Sep.        -0.32       -0.31      -0.27     Beat    13.3
 30 2021                                                
 Jun. 30 2021  -0.27       -0.27      -0.28     Missed  -0.8​
 Mar. 31 2021  -0.80       -0.80      -12.27    Missed  -1,432
                                                        .3
 This summary was machine generated March 20 at 12:44 GMT.  All
figures in US dollars  unless otherwise stated